Description: The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index (the "Underlying Index"). The Underlying Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals which also meet other eligibility criteria determined by NASDAQ, including minimum market capitalization and liquidity requirements. The Fund generally invests at least 90% of its assets in securities of the Underlying Index and in depositary receipts representing securities of the Underlying Index.
|BIIB||Biogen Idec Inc||8.86%|
|VRTX||Vertex Pharmaceuticals Inc.||3.67%|
|BMRN||Biomarin Pharmaceutical Inc.||2.49%|
Data is provided by Zacks Investment Research